OR-1855, a major active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. References: [1]. Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. [2]. Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.

纯度：≥98%

CAS：101328-85-2